Preserving the Pre-cardial Fat Pad During Sleeve Gastrectomy on Postoperative Gastroesophageal Reflux
Key facts
- Who runs it
- Beijing Chao Yang Hospital
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Active, not recruiting
- People taking part
- 50 people, planned
- Started
- 1 Jul 2024
- Expected to end
- 30 Dec 2026
- Type of study
- Interventional, 2 groupsOne group gets no study treatment, for comparison.
- Treatments tested
- Preserve pre-cardial fat pad
- Dissect pre-cardial fat pad
- Record updated
- 13 December 2024
Who can take part
- Age
- 16 years to 65 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (14)Hide the full registry criteria
Who can take part
- BMI ≥ 32.5 kg/m2 with or without T2DM
- 27.5 kg/ m2 < BMI < 32.5 kg/m2 with T2DM but failed conservative treatment and combined with at least two metabolic diseases or comorbidities
- Duration of T2DM ≤15 years with fasting Cpeptide ≥ 50% of normal lower limit
- Waist circumference: male ≥ 90 cm, female ≥ 85 cm
- Age within 16~65 years old
Who cannot take part
- The patient refuses surgery
- Long-term use of antidepressant drugs
- A history of mental illness and neurological disease
- GERD preoperatively
- Hiatus hernia approved by gastroscopy preoperatively
- Pregnancy
- Combined with pituitary tumor
- Long-term use of immunosuppressants
- Situations in which the investigator or other examiner considers from the enrolled study that there are good reasons for nonconformity: if there are potential inconsistencies with the clinical protocol
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Gastroesophageal reflux disease (GERD) is one of the most common chronic conditions that can affect one's quality of life. Laparoscopic sleeve gastrectomy (LSG) has become a popular technique and currently is the most frequently practiced surgical operation to treat obesity today. However, the prevalence of GERD following SG can be fairly high. Several studies have noted an incidence between 6% and 47%.
Read full original descriptionShow less
The angle of His is important for the maintenance of esophageal anti-reflux ability, and prevent GERD. Most SG operating consensus recommends surgeons should stay at least 1 cm away from the angle of His. However, on consensus was reached about the pre-cardial fat pad should be routinely dissected or not to avoid leaving behind a large fundus consensus.
The investigators propose to perform a prospective randomized controlled study to dissect the pre-cardial fat pad or not in obese patients followig sleeve gastrectomy to prevent GERD.
The 2 groups in the trial
- Preserve pre-cardial fat padNo study treatment, for comparison
For this group, a sleeve was fashioned starting 4 cm proximal to the pylorus using serial applications of an 60 stapler over a 36Fr oro-gastric bougie. A security distance of 10 mm lateral to the esophagus is respected without dissection of pre-cardial fat pad.
- Dissect pre-cardial fat padTreatment being tested
For this group, a sleeve was fashioned starting 4 cm proximal to the pylorus using serial applications of an 60 stapler over a 36Fr oro-gastric bougie. Dissect the pre-cardial fat pad, and a security distance of 10 mm lateral to the esophagus is respected.
Treatment: Preserve pre-cardial fat pad and Dissect pre-cardial fat pad
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Prospective Randomized Controlled Study on the Impact of Preserving the Pre-cardial Fat Pad During Sleeve Gastrectomy on Postoperative Gastroesophageal Reflux
- Record updated
- 13 December 2024